Trium Capital LLP Invests $7.54 Million in AstraZeneca PLC (NASDAQ:AZN)

Trium Capital LLP acquired a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 102,641 shares of the company's stock, valued at approximately $7,544,000. AstraZeneca makes up approximately 0.9% of Trium Capital LLP's portfolio, making the stock its 11th largest holding.

Other large investors have also added to or reduced their stakes in the company. Confluence Investment Management LLC bought a new position in shares of AstraZeneca during the first quarter valued at about $27,000. FNY Investment Advisers LLC purchased a new position in AstraZeneca in the first quarter valued at $29,000. Banque Transatlantique SA acquired a new position in AstraZeneca in the 4th quarter valued at about $26,000. Highline Wealth Partners LLC raised its holdings in shares of AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after purchasing an additional 340 shares in the last quarter. Finally, Mascagni Wealth Management Inc. purchased a new stake in AstraZeneca during the fourth quarter worth about $29,000. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Trading Up 0.6%

Shares of AstraZeneca stock opened at $70.02 on Wednesday. The business has a fifty day simple moving average of $70.74 and a two-hundred day simple moving average of $70.71. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a market capitalization of $217.15 billion, a price-to-earnings ratio of 28.12, a P/E/G ratio of 1.28 and a beta of 0.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same period in the previous year, the business posted $2.06 earnings per share. The business's quarterly revenue was up 7.2% compared to the same quarter last year. Research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas began coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.